Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK4 | Q16654 | 1/20 | 0.42 |
| ▸ | GRM1 | Q13255 | 8/20 | 0.39 |
| ▸ | GRM5 | P41594 | 7/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30086990 | 0.89 | PDK4 (0.53) | PDK4GRM1GRM5PDE10ANAMPT | |
| SCHEMBL20919267 | 0.89 | PDK4 (0.53) | PDK4GRM1GRM5PDE10ANAMPT | |
| SCHEMBL31284271 | 0.84 | NR1H2 (0.42) | PDK4GRM1GRM5PDE10AMAPT | |
| SCHEMBL31284146 | 0.84 | NR1H2 (0.42) | PDK4GRM1GRM5PDE10AMAPT | |
| SCHEMBL25345866 | 0.81 | PDE10A (0.49) | PDK4GRM1GRM5PDE10ANAMPT | |
| SCHEMBL31155284 | 0.81 | PDE10A (0.49) | PDK4GRM1GRM5PDE10ANAMPT | |
| SCHEMBL25362816 | 0.80 | GRM1 (0.41) | PDK4GRM1GRM5PDE10AKDM4E | |
| SCHEMBL30496081 | 0.80 | GRM1 (0.41) | PDK4GRM1GRM5PDE10AKDM4E | |
| SCHEMBL31180279 | 0.78 | PDK4 (0.55) | PDK4GRM1GRM5PDE10ANAMPT | |
| SCHEMBL31180085 | 0.78 | PDK4 (0.55) | PDK4GRM1GRM5PDE10ANAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230019491-A1 | PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF | EMD Serono Research and Development Institute, Inc. | 2023-01-19 | — | — | US | disclosed |
| WO-2019079373-A1 | PYRIMIDINE TBK/IKKε INHIBITOR COMPOUNDS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230019491-A1 | PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF | DTYMK, TBKBP1, NFKBIA | PDK4 339/4885GRM1 3695/4885GRM5 3182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.